Menu Search
Equities

Teladoc Health Inc

4LL:STU

Teladoc Health Inc

Actions
  • Price (EUR)8.96
  • Today's Change-0.296 / -3.20%
  • Shares traded800.00
  • 1 Year change-38.79%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Teladoc Health Inc grew revenues 8.13% from 2.41bn to 2.60bn while net income improved from a loss of 13.66bn to a smaller loss of 220.37m.
Gross margin70.82%
Net profit margin-37.91%
Operating margin-38.92%
Return on assets-24.99%
Return on equity-51.65%
Return on investment-30.10%
More ▼

Cash flow in USDView more

In 2023, Teladoc Health Inc increased its cash reserves by 22.38%, or 205.49m. The company earned 350.02m from its operations for a Cash Flow Margin of 13.45%. In addition the company generated 10.85m cash from financing while 156.35m was spent on investing.
Cash flow per share-3.55
Price/Cash flow per share--
Book value per share8.77
Tangible book value per share-1.58
More ▼

Balance sheet in USDView more

Teladoc Health Inc has a Debt to Total Capital ratio of 50.55%, a lower figure than the previous year's 67.04%.
Current ratio1.73
Quick ratio1.69
Total debt/total equity1.02
Total debt/total capital0.5055
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.